Cerebrovascular disease is a significant health concern that threatens people’s health and life. About 80% of its burden comes from ischaemic stroke. Early reperfusion therapy is the key to timely restore blood flow to salvageable ischaemic brain tissue. Reviewing the history of reperfusion therapy for ischaemic stroke, there have been two major breakthroughs: in 1995, following the publication of the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study, thrombolytic therapy with intravenous alteplase significantly reduced disability and improved the quality of life for patients who had a stroke, marking the beginning of the era of reperfusion therapy for ischaemic stroke. Twenty years later, in 2015, several large clinical trials demonstrated that endovascular thrombectomy, in addition to intravenous thrombolysis with alteplase, further improved rate of recanalisation and reduced disability among patients who had a stroke. These new breakthrough treatment propelled reperfusion therapy into another new era. In recent years, the establishment of organised stroke care systems has provided a strong momentum perfusion therapy for ischaemic stroke. The establishment of stroke centres at all levels and the application and promotion of mobile stroke units in our country have significantly reduced prehospital and in-hospital delays to treat patients who had a stroke, therefore improved the effectiveness of reperfusion therapy. Today, the …

中文翻译：

---

CSA 宣布下一代缺血性中风再灌注疗法

脑血管疾病是威胁人们健康和生命的重大健康问题。大约80%的负担来自缺血性中风。早期再灌注治疗是及时恢复可挽救缺血脑组织血流的关键。回顾缺血性脑卒中再灌注治疗的历史，有两大突破：1995年，美国国家神经疾病和脑卒中研究所（NINDS）发表rt-PA脑卒中研究后，静脉阿替普酶溶栓治疗显着降低了残疾率和死亡率。改善了中风患者的生活质量，标志着缺血性中风再灌注治疗时代的开始。二十年后的 2015 年，几项大型临床试验表明，除了阿替普酶静脉溶栓之外，血管内血栓切除术进一步提高了中风患者的再通率并减少了残疾。这些新的突破性治疗将再灌注治疗推入了另一个新时代。近年来，有组织的脑卒中救治体系的建立，为缺血性脑卒中的灌注治疗提供了强劲动力。我国各级脑卒中中心的建立以及移动脑卒中救治中心的应用和推广，显着减少了脑卒中患者的院前和院内延误救治，提高了再灌注治疗的有效性。今天，…